Literature DB >> 16203087

Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice.

Jorge Aguiar1, Julio Fernández, Anselmo Aguilar, Yssel Mendoza, María Vázquez, José Suárez, Jorge Berlanga, Silian Cruz, Gerardo Guillén, Luis Herrera, Luis Velázquez, Nieves Santos, Nelson Merino.   

Abstract

The objective of this work was the generation of an animal model of the SCA2 disease for future studies on the benefits of therapeutic molecules and neuropathological mechanisms that underline this human disorder. The transgenic fragment was microinjected into pronuclei of B6D2F1 X OF1 mouse hybrid strain. For Northern blots, RNAs were hybridized with a human cDNA fragment from the SCA2 gene and a mouse beta-actin cDNA fragment. Monoclonal antibody directed to the N-terminal of the ataxin 2 protein with 22Q was used for Western blot analysis. A rotating rod apparatus was utilized to measure motor coordination of mice. Immunohistochemical detection of Purkinje neurons was performed with anti-calbindin 28K as primary antibody. Ubiquitous expression of the SCA2 transgene with 75 CAG repeats regulated by the SCA2 self promoter was obtained after generation of our transgenic mice. Analysis of transgenic mice revealed significant differences of motor coordination compared with the wild type littermates. Specific degeneration of Purkinje neurons and transgene over-expression in the brain, liver and skeletal muscle, rather than in lungs and kidneys was also observed, resembling the expression pattern of the ataxin 2 in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203087     DOI: 10.1016/j.neulet.2005.09.020

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

2.  Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Authors:  Ilya Bezprozvanny; Thomas Klockgether
Journal:  Drugs Future       Date:  2009-12       Impact factor: 0.148

Review 3.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

Review 4.  A comprehensive review of spinocerebellar ataxia type 2 in Cuba.

Authors:  Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Julio Cesar García-Rodríguez; Luis Enrique Almaguer-Mederos; Tania Cruz-Mariño; José Miguel Laffita-Mesa
Journal:  Cerebellum       Date:  2011-06       Impact factor: 3.847

5.  Consensus Paper: Strengths and Weaknesses of Animal Models of Spinocerebellar Ataxias and Their Clinical Implications.

Authors:  Jan Cendelin; Marija Cvetanovic; Mandi Gandelman; Hirokazu Hirai; Harry T Orr; Stefan M Pulst; Michael Strupp; Filip Tichanek; Jan Tuma; Mario Manto
Journal:  Cerebellum       Date:  2021-08-10       Impact factor: 3.648

6.  Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro.

Authors:  Guangbin Xia; Katherine Santostefano; Takashi Hamazaki; Jilin Liu; S H Subramony; Naohiro Terada; Tetsuo Ashizawa
Journal:  J Mol Neurosci       Date:  2012-12-09       Impact factor: 3.444

Review 7.  Spinocerebellar ataxia 2 (SCA2).

Authors:  Isabel Lastres-Becker; Udo Rüb; Georg Auburger
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 8.  Oxidative stress as a cofactor in spinocerebellar ataxia type 2.

Authors:  Mariela Guevara-García; Lizette Gil-del Valle; Luis Velásquez-Pérez; Julio César García-Rodríguez
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

9.  Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2.

Authors:  Stephen T Hansen; Pratap Meera; Thomas S Otis; Stefan M Pulst
Journal:  Hum Mol Genet       Date:  2012-10-18       Impact factor: 6.150

Review 10.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.